• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床验证吸烟与乳腺癌免疫微环境的关系。

Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer.

机构信息

Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

出版信息

J Transl Med. 2019 Jan 7;17(1):13. doi: 10.1186/s12967-019-1773-y.

DOI:10.1186/s12967-019-1773-y
PMID:30616624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6323676/
Abstract

BACKGROUND

The immune tumor microenvironment (iTME) is thought to affect the response to chemotherapy, and tumor-infiltrating lymphocytes (TILs) are often used as an indicator to evaluate the iTME. Smoking is involved in carcinogenesis, the relationship between smoking and the iTME of lung cancer has been reported. We hypothesized that smoking would affect the iTME of breast cancer and aimed to examine this relationship based on the amount of pre-diagnosis smoking and the subsequent effects on treatment response and prognosis.

METHODS

This retrospective study evaluated data from 149 patients who underwent preoperative chemotherapy for triple-negative or HER2-enriched breast cancer. TILs were assessed in biopsy specimens at diagnosis. The data of all patients were used to calculate each patient's smoking amount based on pack-years.

RESULTS

Relative to the low smoking group, the high smoking group had a significant greater TILs density (p = 0.043) and a significantly better pathological complete response (pCR) rate (p = 0.042). However, there was no significant difference according to smoking amount in disease-free survival (p = 0.114) or overall survival (p = 0.347).

CONCLUSIONS

Smoking may influence the iTME, with an activated iTME being associated with pCR rate. Therefore, controlled activation of the microenvironment in this setting may help improve patients' prognosis.

摘要

背景

免疫肿瘤微环境(iTME)被认为会影响化疗的反应,肿瘤浸润淋巴细胞(TILs)常被用作评估 iTME 的指标。吸烟与癌症的发生有关,已经有报道称吸烟与肺癌的 iTME 之间存在关系。我们假设吸烟会影响乳腺癌的 iTME,并旨在根据诊断前吸烟量以及随后对治疗反应和预后的影响来检验这种关系。

方法

这项回顾性研究评估了 149 名接受三阴性或 HER2 富集型乳腺癌术前化疗的患者的数据。在诊断时对活检标本中的 TILs 进行评估。根据吸烟包年数,利用所有患者的数据计算每位患者的吸烟量。

结果

与低吸烟组相比,高吸烟组的 TILs 密度显著更高(p=0.043),病理完全缓解(pCR)率显著更高(p=0.042)。然而,根据吸烟量,无病生存率(p=0.114)或总生存率(p=0.347)没有显著差异。

结论

吸烟可能会影响 iTME,激活的 iTME 与 pCR 率相关。因此,在这种情况下控制微环境的激活可能有助于改善患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f9/6323676/91642d587369/12967_2019_1773_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f9/6323676/91642d587369/12967_2019_1773_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65f9/6323676/91642d587369/12967_2019_1773_Fig1_HTML.jpg

相似文献

1
Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer.临床验证吸烟与乳腺癌免疫微环境的关系。
J Transl Med. 2019 Jan 7;17(1):13. doi: 10.1186/s12967-019-1773-y.
2
Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.乳腺癌患者接受艾日布林化疗与肿瘤微环境中癌症进展类型的研究。
J Transl Med. 2018 Mar 9;16(1):54. doi: 10.1186/s12967-018-1443-5.
3
Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.术前化疗乳腺癌患者的体重指数与肿瘤免疫应答的临床验证。
BMC Cancer. 2021 Oct 20;21(1):1129. doi: 10.1186/s12885-021-08857-7.
4
Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer.验证钙通道阻滞剂对乳腺癌免疫微环境的影响。
BMC Cancer. 2019 Jun 24;19(1):615. doi: 10.1186/s12885-019-5828-5.
5
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.浸润淋巴细胞与不同亚型乳腺癌患者预后的关系:新辅助化疗治疗 3771 例患者的汇总分析
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
6
Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer.通过术前化疗中免疫微环境监测避免乳腺癌腋窝淋巴结清扫的可能性。
J Transl Med. 2018 Nov 19;16(1):318. doi: 10.1186/s12967-018-1692-3.
7
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.原发性全身化疗后丰富的肿瘤浸润淋巴细胞预示着雌激素受体阳性/HER2 阴性乳腺癌预后不良。
Breast Cancer Res Treat. 2018 Feb;168(1):135-145. doi: 10.1007/s10549-017-4575-z. Epub 2017 Nov 22.
8
Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.利用肿瘤浸润淋巴细胞预测化疗(帕妥珠单抗、曲妥珠单抗、多西他赛)对HER2阳性乳腺癌的治疗效果。
Anticancer Res. 2017 Oct;37(10):5623-5630. doi: 10.21873/anticanres.11997.
9
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.肿瘤浸润淋巴细胞与曲妥珠单抗联合拉帕替尼治疗 HER2 阳性早期乳腺癌的病理完全缓解和无事件生存的相关性:NeoALTTO 试验的二次分析。
JAMA Oncol. 2015 Jul;1(4):448-54. doi: 10.1001/jamaoncol.2015.0830.
10
Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.利用肿瘤浸润淋巴细胞通过亚型预测乳腺癌新辅助化疗的治疗反应
Anticancer Res. 2018 Apr;38(4):2311-2321. doi: 10.21873/anticanres.12476.

引用本文的文献

1
A dataset of chronic nicotine-induced genes in breast cancer cells.一组乳腺癌细胞中慢性尼古丁诱导基因的数据集。
Data Brief. 2025 Apr 22;60:111573. doi: 10.1016/j.dib.2025.111573. eCollection 2025 Jun.
2
S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers.S100A8/A9先天免疫信号传导是驱动吸烟相关乳腺癌进展的一种独特机制。
Oncogene. 2025 Apr;44(15):1051-1062. doi: 10.1038/s41388-025-03276-5. Epub 2025 Jan 25.
3
The Impact of Treatment for Smoking on Breast Cancer Patients' Survival.

本文引用的文献

1
Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.乳腺癌患者接受艾日布林化疗与肿瘤微环境中癌症进展类型的研究。
J Transl Med. 2018 Mar 9;16(1):54. doi: 10.1186/s12967-018-1443-5.
2
Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.利用肿瘤浸润淋巴细胞(TILs)预测乳腺癌患者对艾日布林化疗的治疗反应。
PLoS One. 2017 Feb 6;12(2):e0170634. doi: 10.1371/journal.pone.0170634. eCollection 2017.
3
Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.
吸烟治疗对乳腺癌患者生存的影响。
Cancers (Basel). 2022 Mar 12;14(6):1464. doi: 10.3390/cancers14061464.
4
Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.胰腺癌相关的肿瘤浸润 B 和 T 细胞 repertoire 与宿主和肿瘤特征有关。
Front Immunol. 2021 Sep 23;12:730746. doi: 10.3389/fimmu.2021.730746. eCollection 2021.
5
Nicotine promotes breast cancer metastasis by stimulating N2 neutrophils and generating pre-metastatic niche in lung.尼古丁通过刺激 N2 中性粒细胞和在肺部产生转移前生态位来促进乳腺癌转移。
Nat Commun. 2021 Jan 20;12(1):474. doi: 10.1038/s41467-020-20733-9.
6
No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis.吸烟状态对乳腺癌肿瘤浸润淋巴细胞、新辅助化疗反应及预后无影响。
Cancers (Basel). 2020 Oct 12;12(10):2943. doi: 10.3390/cancers12102943.
7
Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium.吸烟在鳞状细胞癌和正常气道上皮中的免疫调节及免疫治疗意义
Oncotarget. 2019 Jun 11;10(39):3835-3839. doi: 10.18632/oncotarget.26982.
8
Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?肿瘤浸润淋巴细胞(TILs)能否成为早期和局部晚期乳腺癌淋巴结状态的预测因素?
J Clin Med. 2019 Apr 22;8(4):545. doi: 10.3390/jcm8040545.
在完全切除的非小细胞肺癌中,肿瘤浸润淋巴细胞的预后价值因组织学类型和吸烟习惯而异。
Ann Oncol. 2016 Nov;27(11):2117-2123. doi: 10.1093/annonc/mdw319. Epub 2016 Aug 8.
4
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.乳腺癌亚型中肿瘤浸润淋巴细胞的发生率和幅度的变化:系统评价。
JAMA Oncol. 2016 Oct 1;2(10):1354-1360. doi: 10.1001/jamaoncol.2016.1061.
5
A case-control analysis of smoking and breast cancer in African American women: findings from the AMBER Consortium.非裔美国女性吸烟与乳腺癌的病例对照分析:来自AMBER联盟的研究结果。
Carcinogenesis. 2016 Jun;37(6):607-15. doi: 10.1093/carcin/bgw040. Epub 2016 Apr 7.
6
Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.浸润性肿瘤 CD8/FOXP3 淋巴细胞比值预测侵袭性乳腺癌新辅助化疗的治疗反应。
Br J Surg. 2016 Jun;103(7):845-54. doi: 10.1002/bjs.10127. Epub 2016 Mar 8.
7
Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis.通过富含淋巴细胞的间质比例定义淋巴细胞为主型乳腺癌及其在常规组织病理学诊断中的意义。
Pathol Int. 2015 Dec;65(12):644-51. doi: 10.1111/pin.12355. Epub 2015 Nov 4.
8
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.RAS/MAPK激活与三阴性乳腺癌中肿瘤浸润淋巴细胞减少相关:MEK与PD-1/PD-L1免疫检查点抑制剂之间的治疗协同作用
Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29.
9
Partial mastectomy using manual blunt dissection (MBD) in early breast cancer.早期乳腺癌采用手法钝性分离(MBD)进行保乳手术。
BMC Surg. 2015 Oct 22;15:117. doi: 10.1186/s12893-015-0102-5.
10
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.基质 CD8+T 细胞密度——非小细胞肺癌 TNM 分期的有前途补充。
Clin Cancer Res. 2015 Jun 1;21(11):2635-43. doi: 10.1158/1078-0432.CCR-14-1905. Epub 2015 Feb 13.